EUVIMEDEUVIMED entdecken
Crossref

Is metabolic dysfunction-associated steatotic liver disease truly irrelevant? Unmasking the heterogeneity and confounders in pancreatic cancer outcomes

Zhe-Kun Xiong, Yu-Zi Jiang, Yan-Hua Lin, Jian-Dong Cao, Tao-Ying Deng, Yi-Yuan Zheng

World Journal of Gastroenterology · 21.07.2026 · 32 (27)

DOI: 10.3748/wjg.119356 ↗

Kurz gefasst

Fachartikel in der Zeitschrift World Journal of Gastroenterology, online erschienen am 21.07.2026. Verfasst von Zhe-Kun Xiong und 5 weiteren Autor:innen. Die Arbeit nennt 61 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction-associated steatotic liver disease (MASLD) has no significant impact on liver-metastatic patterns or survival outcomes in patients with pancreatic cancer. While the negative findings are clinically appealing, several issues may limit a definitive biological interpretation. First, the use of steatosis-weighted, noninvasive surrogates may be prone to misclassification in pancreatic cancer, where cachexia, sarcopenia, and systemic inflammation can distort these components, thereby attenuating true associations toward the null. Second, accumulating evidence has suggested that MASLD is highly heterogeneous, in which adverse oncologic outcomes are more consistently linked to metabolic inflammation and fibrosis rather than steatosis alone and pooling these phenotypes may dilute signals from high-risk subgroups. Third, in pancreatic cancer with short survival, death is a major competing event, conventional time-to-event analyses without competing-risk frameworks may thereby underestimate the metastasis-related effect. Additionally, mechanistic research supports the concept of a pre-metastatic hepatic niche that is driven by inflammation and metabolic reprogramming in pancreatic cancer. Therefore, we conclude that the statistical absence of correlation should not be conflated with the absence of biological causation. Instead, future studies incorporating fibrosis-focused phenotyping, treatment-aware modeling, and competing-risk analyses are warranted to clarify which MASLD subtypes may meaningfully influence metastasis and survival.

Zitieren

APA

Xiong, Z., Jiang, Y., Lin, Y., Cao, J., Deng, T., & Zheng, Y. (2026). Is metabolic dysfunction-associated steatotic liver disease truly irrelevant? Unmasking the heterogeneity and confounders in pancreatic cancer outcomes. World Journal of Gastroenterology, 32(27). https://doi.org/10.3748/wjg.119356

Vancouver

Xiong Z, Jiang Y, Lin Y, Cao J, Deng T, Zheng Y. Is metabolic dysfunction-associated steatotic liver disease truly irrelevant? Unmasking the heterogeneity and confounders in pancreatic cancer outcomes. World Journal of Gastroenterology. 2026;32(27). doi:10.3748/wjg.119356

BibTeX
@article{Xiong2026,
  author = {Xiong, Zhe-Kun and Jiang, Yu-Zi and Lin, Yan-Hua and Cao, Jian-Dong and Deng, Tao-Ying and Zheng, Yi-Yuan},
  title = {Is metabolic dysfunction-associated steatotic liver disease truly irrelevant? Unmasking the heterogeneity and confounders in pancreatic cancer outcomes},
  journal = {World Journal of Gastroenterology},
  year = {2026},
  volume = {32},
  number = {27},
  doi = {10.3748/wjg.119356}
}
Kostenlos starten →